He is the first Chinese to win the Alberni Biomedical Award, the highest award in biomedicine in the United States, and the first scientist from Chinese mainland the Pacific Northwest National Laboratory to conduct scientific research, and has four academician laurels, of which 3 academician titles are from the United States, and its scientific research level is self-evident. Now, he has made another achievement in the fight against COVID-19.
He is Xie Xiaoliang, a foreign academician of the Chinese Academy of Sciences.
However, it was this international leader in the basic scientific research of biophysical chemistry, the founder of single-molecule enzymology and one of the founders of single-molecule biophysical chemistry, who pioneered coherent Raman scattering microscopy technology and single-cell genomics, but gave up tenured professors at Harvard University and returned to China full-time.
Some may be surprised by his return to China, but not by those who know him.
Xie Xiaoliang has won the NIH Pioneer Award, and there will be 500,000 US dollars in funding every year, which can be freely disposed of for 5 consecutive years, which shows that his funds are abundant. Not only that, he won two such awards. It can be seen that its treatment in the United States is absolutely generous, and it has won many American awards, which may be the reason why Xie Xiaoliang returned to China and surprised many people.
However, he said this: After studying and working in the United States for more than thirty years, I chose to return to Peking University and renew the frontier with Yanyuan - this is not only the place of enlightenment in my life, but also the place where my scientific research returns.
In fact, in 2001, Xie Xiaoliang was appointed as a visiting professor at the School of Chemistry of Peking University and a member of the Academic Committee of the State Key Laboratory of Molecular Dynamics and Steady-State Structures in China; in 2008, he became a chair professor of the Yangtze River Scholar Award Program in the School of Life Sciences of Peking University; in 2010, he presided over the establishment of the Biodynamic Optical Imaging Center (biopic) of Peking University; on September 19, 2014, the team led by Xie Xiaoliang completed the world's first case." Malbac Baby", the event marked that China's preimplantation genetic diagnosis technology is at the world's leading level; in 2016, he established the Beijing Future Genetic Diagnosis High-precision Innovation Center (iCG); in 2017, he became a foreign academician of the Chinese Academy of Sciences; and in July 2018, he officially returned to Peking University full-time. During this period, he became a member of the National Medical College in 2016. It can be seen that Academician Xie Xiaoliang has also supported the development of Scientific Research in China for a long time, and has also maintained contact with domestic scientific research departments for a long time, so his return to China is not accidental.
In November 2019, Xie Xiaoliang served as the director of the Department of Science at Peking University.
In terms of medicine, Xie Xiaoliang has continued to forge ahead, and his team has avoided the transmission of diseases to more than 300 families with single-gene genetic diseases in China, and has avoided the transfer of chromosomal abnormal embryos for thousands of pregnant women, effectively reducing the occurrence of chromosomal abnormal diseases such as miscarriage and Down syndrome. Probably most people are not deeply affected by genetic diseases. However, it is because of this technical support that Chinese truly achieve eugenics.
In addition, at present, the global scientific research against the new crown epidemic is divided into two ways, aiming at vaccines and drugs to accelerate the sprint, and China's scientific research team is also non-stop. Vaccines may be produced at the end of the year, and under the new crown epidemic this year, Academician Xie Xiaoliang's team is also fighting ceaselessly, in the absence of specific drugs, he has achieved new results, and his research and development results have been published in the internationally renowned academic journal "Cell" on May 17.
"This is an important stage achievement of scientific anti-epidemic."
Xie Xiaoliang's team and its collaborators have achieved this achievement in less than three months, and Xie Xiaoliang said that the results of animal experiments are very satisfactory and clinical trials are being actively promoted. If it goes well, it is expected that a potent drug will be successfully developed this winter.
From returning to China full-time in 2018, to now, making new achievements in the fight against new crown pneumonia, Xie Xiaoliang has let the world see the power of Chinese and brought hope to mankind.
Come on China! Chinese researchers cheers!